Cardio-renal-metabolic modeling in Asia-Pacific: projections of clinical and economic burden and empagliflozin’s impact on burden reduction

Lijoy Varghese

doi:10.1080/13696998.2025.2590401

December 2, 2025Journal of Medical EconomicsOpen Access

Cardio-renal-metabolic modeling in Asia-Pacific: projections of clinical and economic burden and empagliflozin’s impact on burden reduction

View Full Paper

Ask AI

Bookmark

Share

Key Points

Projected increases in economic burden due to comorbid CRM disease affect healthcare resources.
Empagliflozin usage may reduce clinical and economic burdens in the Asia-Pacific region.
Economic burden highlights the need for effective interventions in managing CRM diseases.
The findings underscore the importance of SGLT2 inhibitors like empagliflozin in addressing healthcare challenges.

Implication

Assessment projects increased economic burden in Asia-Pacific due to CRM disease, suggesting empagliflozin may mitigate this.

Abstract

Substantial increases in comorbid CRM disease prevalence and associated healthcare resource strain in APAC are expected over the next decade. Guideline-directed SGLT2 inhibitor use, with empagliflozin as an example, may alleviate regional clinical and economic burden.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lijoy Varghese (2025) studied this question.

synapsesocial.com/papers/69337ce8b3f947a0a125a10a https://doi.org/10.1080/13696998.2025.2590401

View Full Paper

Ask AI

Bookmark

Share

Cardio-renal-metabolic modeling in Asia-Pacific: projections of clinical and economic burden and empagliflozin’s impact on burden reduction

Key Points

Implication

Abstract

Discussion

Cite This Study

Cardio-renal-metabolic modeling in Asia-Pacific: projections of clinical and economic burden and empagliflozin’s impact on burden reduction

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading